Hidrasec (Racecadotril) for Acute Diarrhea in Adults
Hidrasec (racecadotril) is a reasonable option for treating mild-to-moderate acute non-invasive diarrhea in adults, though it is not specifically mentioned in major U.S. guidelines and should only be used as adjunctive therapy after ensuring adequate hydration with oral rehydration solution (ORS).
Primary Treatment Framework
The 2017 IDSA guidelines establish that oral rehydration solution remains the cornerstone of acute diarrhea management 1. Ancillary treatments like antimotility or antisecretory agents can be considered once the patient is adequately hydrated, but they are not substitutes for fluid and electrolyte therapy 1.
Racecadotril's Role and Evidence
Mechanism and Efficacy
Racecadotril works as an enkephalinase inhibitor with antisecretory effects on the intestinal tract, reducing water and electrolyte secretion without affecting intestinal motility 2, 3. This distinguishes it from loperamide, which slows intestinal transit.
The most recent and highest-quality evidence (2025 meta-analysis) demonstrates that racecadotril is superior to loperamide for adult infectious diarrhea, showing better clinical response rates and significantly fewer adverse effects 4. This systematic review of randomized controlled trials found racecadotril improved clinical outcomes with moderate heterogeneity (I² = 56%) and reduced constipation and abdominal discomfort compared to loperamide.
Comparative Effectiveness
Multiple studies consistently show:
- Similar speed of symptom resolution compared to loperamide (median duration 13-19.5 hours) 5, 6
- Significantly less rebound constipation (9.8-16% vs 18.7-29% with loperamide) 6, 7
- Better reduction in abdominal pain and distension 7
- Clinical success rates of 92-95.7% 5, 7
Dosing
According to FDA labeling, for adults and children ≥12 years: 2-4 teaspoons (25-50 mg) every 4-6 hours, not exceeding 6 doses in 24 hours 8. Note that international dosing typically uses 100 mg three times daily in clinical trials 5, 6, 7.
Contraindications and Safety Considerations
When NOT to Use Racecadotril:
- Inflammatory diarrhea or diarrhea with fever - antimotility/antisecretory agents should be avoided when toxic megacolon is a risk 1
- Suspected STEC O157 or Shiga toxin-producing infections - avoid all antimicrobial and antimotility therapies 1
- Children under 12 years without specific guidance (FDA labeling) 8
- Before adequate hydration is established 1
Safety Profile:
Racecadotril has tolerability similar to placebo 2. One study noted higher itching rates (28.6% vs 0% with loperamide) 5, but overall adverse event rates are lower than loperamide (14.2% vs 23.9%) 7. No serious adverse events have been reported 3.
Clinical Algorithm
- First: Assess hydration status and initiate ORS - this is non-negotiable 1
- Rule out inflammatory diarrhea - check for fever, bloody stools, severe abdominal pain
- Once adequately hydrated, consider racecadotril as adjunctive therapy for symptom relief
- Avoid in high-risk scenarios: immunocompromised patients requiring empiric antibiotics, suspected invasive pathogens, or when toxic megacolon is possible
Important Caveats
- Not mentioned in U.S. IDSA guidelines: The 2017 IDSA guidelines specifically mention loperamide but not racecadotril, suggesting limited adoption in U.S. practice 1
- More widely used internationally: Most evidence comes from studies in Europe, Asia, Africa, and South America 7, 2
- Pediatric evidence is weak: A 2019 Cochrane review found insufficient evidence to support routine use in children under 5 years 9
The key principle: Racecadotril should never replace proper hydration therapy but can be added to reduce symptom duration and severity in immunocompetent adults with non-invasive acute watery diarrhea.